IRD
NASDAQ · Biotechnology
Opus Genetics Inc
$4.06
-0.25 (-5.80%)
Open$4.23
Previous Close$4.31
Day High$4.35
Day Low$3.96
52W High$7.07
52W Low$1.70
Volume—
Avg Volume1.13M
Market Cap384.68M
P/E Ratio—
EPS$-1.29
SectorBiotechnology
Analyst Ratings
Strong Buy
23 analysts
Price Target
+471.7% upside
Current
$4.06
$4.06
Target
$23.21
$23.21
$16.63
$23.21 avg
$31.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 21.62M | 30.50M | 29.63M |
| Net Income | -75,515,598 | -95,872,532 | -1,185,756 |
| Profit Margin | -349.3% | -331.9% | -4.0% |
| EBITDA | -58,697,507 | -78,660,786 | -1,569,658 |
| Free Cash Flow | — | — | -1,455,645 |
| Rev Growth | -29.1% | -29.1% | +20.7% |
| Debt/Equity | 0.07 | 0.07 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |